Efficacy and Safety of Once‐Weekly and Once‐Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis of Clinical Trials
Authors' conclusion
In T1DM, once-weekly basal insulins appear broadly comparable in reducing HbA1c at week 52. Although icodec showed a higher overall hypoglycemia risk, evidence suggests a comparable risk of severe hypoglycemias between treatments.
Study context
- Population
- Phase 3 clinical trials of basal insulins in T1D; PubMed and Embase searched up to April 202519 studies
- Comparison
- Once-weekly basal insulins vs once-daily basal insulins
- Outcome
- Change in HbA1c
- Follow-up
- Week 26 and 52
Methodological detailsphase 3 clinical trials, Bayesian (CrI)
- Phase 3 clinical trials
- Bayesian (CrI)
Pooled result
As reported in the abstract
week 52
%
- Icodec vs Degludec 100
- −0.17 (95% CrI −0.28 to −0.06)
- Icodec vs Glargine 100
- −0.17 (95% CrI −0.32 to −0.02)
- Icodec vs Detemir
- −0.17 (95% CrI −0.32 to −0.02)
- Icodec vs NPH
- −0.59 (95% CrI −0.85 to −0.34)
- Efsitora alfa vs NPH
- −0.45 (95% CrI −0.70 to −0.19)
Safety
| Outcome | OR (95% CrI) | |
|---|---|---|
| Overall hypoglycemia · week 52Icodecvs Degludec 100CrI | 1.64 (1.07–2.54) | |
| Overall hypoglycemia · week 52Icodecvs DetemirCrI | 2.08 (1.01–4.39) | |
| 0.20.5125Odds ratio (log scale) |
Severe hypoglycemia and serious adverse events (AEs)
- Icodec: no increased risk of severe hypoglycemias or serious AEs
Original publication
Efficacy and Safety of Once‐Weekly and Once‐Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis of Clinical Trials. Diabetes Obes Metab. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →